Stanimirović, Julijana

Link to this page

Authority KeyName Variants
orcid::0000-0002-0929-3482
  • Stanimirović, Julijana (27)
Projects

Author's Bibliography

Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?

Panić, Anastasija; Sudar-Milovanović, Emina; Stanimirović, Julijana; Obradović, Milan M.; Zafirović, Sonja; Soskić, Sanja S.; Isenović, Esma R.

(2023)

TY  - JOUR
AU  - Panić, Anastasija
AU  - Sudar-Milovanović, Emina
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10744
AB  - The liver is an organ in which many oxidative processes occur and represents an important target of oxidative stress (OxS). Under physiological conditions of normal mitochondrial homeostasis, hepatocytes effectively remove reactive oxygen species (ROS) by enabling metabolic adaptations and through the antioxidant defence system mechanisms. However, obesity-induced lipid accumulation in the hepatocytes causes significantly elevated production of ROS, reduces oxidative capacity, and increases oxidative stress (OxS). In men, compared with premenopausal women, the development of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in obesity are more prevalent, where oestradiol (E2), the most potent female sex steroid, is proposed as the main culprit. Exogenous oestradiol (E2) administration exerts beneficial effects on antioxidant properties, restores total plasma antioxidant capacity and decreases biomarkers of OxS in ovariectomized animal models. Thus, we hypothesized that E2 treatment in states of obesity could have beneficial effects against OxS in the obese male's liver. We assumed that E2 could directly affect the level of OxS by increasing the level/activity of the AOS enzymes, particularly SOD1, SOD2, GPx, and CAT, in obese males' livers. In addition, we assumed that the level of malondialdehyde (MDA) and protein carbonyl content (PCC) in obese males' livers would be reduced after E2 treatment as a result of E2 inhibitory effect on lipid peroxidation and protein oxidation, respectively. To test our hypothesis, we used the liver of a high-fat (HF) diet-fed male Wistar rats as an animal model of obesity, treated with E2 intraperitoneally (40 μg/kg). Preliminary results from this study support our hypothesis that E2 increases liver protein expression of AOS enzymes: SOD1, GPx, and CAT, in control and HF male rats compared with their respective controls. The protein level of SOD2 and CAT activity was increased in HF treated with E2 compared with non-treated HF rats. Moreover, as we expected, E2 administration significantly decreased the MDA level in both E2-treated groups compared to their controls, while the PCC level was significantly decreased in HF treated group compared with untreated HF rats. In conclusion, the preliminary results we obtained in this study indicate that E2 administration can effectively inhibit the OxS-related processes in the liver in HF diet-induced obesity by increasing AOS enzymes levels and CAT activity, and also by decreasing levels of MDA and PCC. A consequence of our hypothesis is that treatment with E2 may be an innovative way to improve obesity-related liver disease prevention and healing. © 2023 Elsevier Ltd
T2  - Medical Hypotheses
T1  - Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?
VL  - 174
SP  - 111049
DO  - 10.1016/j.mehy.2023.111049
ER  - 
@article{
author = "Panić, Anastasija and Sudar-Milovanović, Emina and Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Soskić, Sanja S. and Isenović, Esma R.",
year = "2023",
abstract = "The liver is an organ in which many oxidative processes occur and represents an important target of oxidative stress (OxS). Under physiological conditions of normal mitochondrial homeostasis, hepatocytes effectively remove reactive oxygen species (ROS) by enabling metabolic adaptations and through the antioxidant defence system mechanisms. However, obesity-induced lipid accumulation in the hepatocytes causes significantly elevated production of ROS, reduces oxidative capacity, and increases oxidative stress (OxS). In men, compared with premenopausal women, the development of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in obesity are more prevalent, where oestradiol (E2), the most potent female sex steroid, is proposed as the main culprit. Exogenous oestradiol (E2) administration exerts beneficial effects on antioxidant properties, restores total plasma antioxidant capacity and decreases biomarkers of OxS in ovariectomized animal models. Thus, we hypothesized that E2 treatment in states of obesity could have beneficial effects against OxS in the obese male's liver. We assumed that E2 could directly affect the level of OxS by increasing the level/activity of the AOS enzymes, particularly SOD1, SOD2, GPx, and CAT, in obese males' livers. In addition, we assumed that the level of malondialdehyde (MDA) and protein carbonyl content (PCC) in obese males' livers would be reduced after E2 treatment as a result of E2 inhibitory effect on lipid peroxidation and protein oxidation, respectively. To test our hypothesis, we used the liver of a high-fat (HF) diet-fed male Wistar rats as an animal model of obesity, treated with E2 intraperitoneally (40 μg/kg). Preliminary results from this study support our hypothesis that E2 increases liver protein expression of AOS enzymes: SOD1, GPx, and CAT, in control and HF male rats compared with their respective controls. The protein level of SOD2 and CAT activity was increased in HF treated with E2 compared with non-treated HF rats. Moreover, as we expected, E2 administration significantly decreased the MDA level in both E2-treated groups compared to their controls, while the PCC level was significantly decreased in HF treated group compared with untreated HF rats. In conclusion, the preliminary results we obtained in this study indicate that E2 administration can effectively inhibit the OxS-related processes in the liver in HF diet-induced obesity by increasing AOS enzymes levels and CAT activity, and also by decreasing levels of MDA and PCC. A consequence of our hypothesis is that treatment with E2 may be an innovative way to improve obesity-related liver disease prevention and healing. © 2023 Elsevier Ltd",
journal = "Medical Hypotheses",
title = "Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?",
volume = "174",
pages = "111049",
doi = "10.1016/j.mehy.2023.111049"
}
Panić, A., Sudar-Milovanović, E., Stanimirović, J., Obradović, M. M., Zafirović, S., Soskić, S. S.,& Isenović, E. R.. (2023). Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?. in Medical Hypotheses, 174, 111049.
https://doi.org/10.1016/j.mehy.2023.111049
Panić A, Sudar-Milovanović E, Stanimirović J, Obradović MM, Zafirović S, Soskić SS, Isenović ER. Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?. in Medical Hypotheses. 2023;174:111049.
doi:10.1016/j.mehy.2023.111049 .
Panić, Anastasija, Sudar-Milovanović, Emina, Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Soskić, Sanja S., Isenović, Esma R., "Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?" in Medical Hypotheses, 174 (2023):111049,
https://doi.org/10.1016/j.mehy.2023.111049 . .

The Role of miRNAs in Metabolic Diseases

Mačvanin, Mirjana; Obradović, Milan M.; Zafirović, Sonja; Stanimirović, Julijana; Isenović, Esma R.

(2023)

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Stanimirović, Julijana
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10757
AB  - Metabolic diseases such as obesity, diabetes, dyslipidemia, and insulin resistance are characterized by glucose and lipid metabolism alterations and represent a global health problem. Many studies have established the crucial role of micro-ribonucleic acids (miRNAs) in controlling metabolic processes in various tissues. miRNAs are single-stranded, highly conserved non-coding RNAs containing 20-24 oligonucleotides that are expressed in a tissue-specific manner. miRNAs mainly interact through base pairing with 3' untranslated regions of target gene mRNAs to promote inhibition of their translation. miRNAs regulate the expression of as many as 30% of the human genes and have a role in crucial physiological processes such as human growth and development, cell proliferation, apoptosis, and metabolism. The number of miRNA molecules with a confirmed role in the pathogenesis of metabolic diseases is quickly expanding due to the availability of high-throughput methodologies for their identification. In this review, we present recent findings regarding the role of miRNAs as endocrine signaling molecules involved in the regulation of insulin production and fat metabolism. We discuss the potential of extracellular miRNAs present in biological fluids miRNAs as biomarkers for the prediction of diabetes and MetS. We also give an updated overview of therapeutic interventions based on antisense oligonucleotides and the CRISPR/Cas9 editing platform for manipulating levels of miRNAs involved in metabolic disorders. © 2023 Bentham Science Publishers.
T2  - Current Medicinal Chemistry
T1  - The Role of miRNAs in Metabolic Diseases
VL  - 30
IS  - 17
SP  - 1922
EP  - 1944
DO  - 10.2174/0929867329666220801161536
ER  - 
@article{
author = "Mačvanin, Mirjana and Obradović, Milan M. and Zafirović, Sonja and Stanimirović, Julijana and Isenović, Esma R.",
year = "2023",
abstract = "Metabolic diseases such as obesity, diabetes, dyslipidemia, and insulin resistance are characterized by glucose and lipid metabolism alterations and represent a global health problem. Many studies have established the crucial role of micro-ribonucleic acids (miRNAs) in controlling metabolic processes in various tissues. miRNAs are single-stranded, highly conserved non-coding RNAs containing 20-24 oligonucleotides that are expressed in a tissue-specific manner. miRNAs mainly interact through base pairing with 3' untranslated regions of target gene mRNAs to promote inhibition of their translation. miRNAs regulate the expression of as many as 30% of the human genes and have a role in crucial physiological processes such as human growth and development, cell proliferation, apoptosis, and metabolism. The number of miRNA molecules with a confirmed role in the pathogenesis of metabolic diseases is quickly expanding due to the availability of high-throughput methodologies for their identification. In this review, we present recent findings regarding the role of miRNAs as endocrine signaling molecules involved in the regulation of insulin production and fat metabolism. We discuss the potential of extracellular miRNAs present in biological fluids miRNAs as biomarkers for the prediction of diabetes and MetS. We also give an updated overview of therapeutic interventions based on antisense oligonucleotides and the CRISPR/Cas9 editing platform for manipulating levels of miRNAs involved in metabolic disorders. © 2023 Bentham Science Publishers.",
journal = "Current Medicinal Chemistry",
title = "The Role of miRNAs in Metabolic Diseases",
volume = "30",
number = "17",
pages = "1922-1944",
doi = "10.2174/0929867329666220801161536"
}
Mačvanin, M., Obradović, M. M., Zafirović, S., Stanimirović, J.,& Isenović, E. R.. (2023). The Role of miRNAs in Metabolic Diseases. in Current Medicinal Chemistry, 30(17), 1922-1944.
https://doi.org/10.2174/0929867329666220801161536
Mačvanin M, Obradović MM, Zafirović S, Stanimirović J, Isenović ER. The Role of miRNAs in Metabolic Diseases. in Current Medicinal Chemistry. 2023;30(17):1922-1944.
doi:10.2174/0929867329666220801161536 .
Mačvanin, Mirjana, Obradović, Milan M., Zafirović, Sonja, Stanimirović, Julijana, Isenović, Esma R., "The Role of miRNAs in Metabolic Diseases" in Current Medicinal Chemistry, 30, no. 17 (2023):1922-1944,
https://doi.org/10.2174/0929867329666220801161536 . .
9
7

Methods for Measurements of Oxidized LDL, Homocysteine and Nitric Oxide as Clinical Parameters of Oxidative Stress and Endothelial Dysfunction

Mačvanin, Mirjana; Stanimirović, Julijana; Isenović, Esma R.

(2022)

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Stanimirović, Julijana
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10545
AB  - Timely and accurate evaluation of clinical parameters associated with endothelial dysfunctionis critical in diagnosing and treating atherosclerosis, which represents a severe health problem, accountingfor at least 30% of deaths globally. A critical early event in the pathogenesis of atherosclerosis is the oxidativemodification of low-density lipoprotein (LDL). Oxidized LDL (OxLDL) represents numerouschanges in lipid and apolipoprotein B (apo B) fractions of LDLs generated by lipid peroxidation. Anotherindicator of perturbed vascular homeostasis is homocysteine (Hcy), an amino acid containing sulfhydrylgroup,an intermediate methionine and cysteine biosynthesis product. The total level of Hcy in plasmacorrelates better than cholesterol with the risk of cardiovascular disease. In addition, nitric oxide (NO)plays an essential role in regulating vascular physiological homeostasis due to its involvement in intravascularfree radical and oxidant reactions. Reduced NO decreases oxidative stress in the vascular wall,which reduces the rate of LDL oxidation and the expression of redox-sensitive genes involved in atherogenesis.Endothelial dysfunction is typically associated with increased levels of OxLDL, decreased nitricoxide (NO), and hyperhomocysteinemia. Thus, OxLDL, Hcy, and NO are representative parameters ofoxidative stress and endothelial dysfunction. Considering the important role of oxLDL, Hcy and NO inoxidative stress, atherogenesis and accompanying endothelial dysfunction, the challenge of the presentwork was to systematically present available methods for reliable measurement of these parameters andassess their potential for the use in the clinical setting. Here we present a comprehensive overview ofanalytical methods for measuring OxLDL, HCy, and NO in biological samples and discuss their advantagesand potential problems regarding their application in clinical settings.
T2  - Current Analytical Chemistry
T1  - Methods for Measurements of Oxidized LDL, Homocysteine and Nitric Oxide as Clinical Parameters of Oxidative Stress and Endothelial Dysfunction
VL  - 18
IS  - 10
SP  - 1040
EP  - 1056
DO  - 10.2174/1573411018666220827142613
ER  - 
@article{
author = "Mačvanin, Mirjana and Stanimirović, Julijana and Isenović, Esma R.",
year = "2022",
abstract = "Timely and accurate evaluation of clinical parameters associated with endothelial dysfunctionis critical in diagnosing and treating atherosclerosis, which represents a severe health problem, accountingfor at least 30% of deaths globally. A critical early event in the pathogenesis of atherosclerosis is the oxidativemodification of low-density lipoprotein (LDL). Oxidized LDL (OxLDL) represents numerouschanges in lipid and apolipoprotein B (apo B) fractions of LDLs generated by lipid peroxidation. Anotherindicator of perturbed vascular homeostasis is homocysteine (Hcy), an amino acid containing sulfhydrylgroup,an intermediate methionine and cysteine biosynthesis product. The total level of Hcy in plasmacorrelates better than cholesterol with the risk of cardiovascular disease. In addition, nitric oxide (NO)plays an essential role in regulating vascular physiological homeostasis due to its involvement in intravascularfree radical and oxidant reactions. Reduced NO decreases oxidative stress in the vascular wall,which reduces the rate of LDL oxidation and the expression of redox-sensitive genes involved in atherogenesis.Endothelial dysfunction is typically associated with increased levels of OxLDL, decreased nitricoxide (NO), and hyperhomocysteinemia. Thus, OxLDL, Hcy, and NO are representative parameters ofoxidative stress and endothelial dysfunction. Considering the important role of oxLDL, Hcy and NO inoxidative stress, atherogenesis and accompanying endothelial dysfunction, the challenge of the presentwork was to systematically present available methods for reliable measurement of these parameters andassess their potential for the use in the clinical setting. Here we present a comprehensive overview ofanalytical methods for measuring OxLDL, HCy, and NO in biological samples and discuss their advantagesand potential problems regarding their application in clinical settings.",
journal = "Current Analytical Chemistry",
title = "Methods for Measurements of Oxidized LDL, Homocysteine and Nitric Oxide as Clinical Parameters of Oxidative Stress and Endothelial Dysfunction",
volume = "18",
number = "10",
pages = "1040-1056",
doi = "10.2174/1573411018666220827142613"
}
Mačvanin, M., Stanimirović, J.,& Isenović, E. R.. (2022). Methods for Measurements of Oxidized LDL, Homocysteine and Nitric Oxide as Clinical Parameters of Oxidative Stress and Endothelial Dysfunction. in Current Analytical Chemistry, 18(10), 1040-1056.
https://doi.org/10.2174/1573411018666220827142613
Mačvanin M, Stanimirović J, Isenović ER. Methods for Measurements of Oxidized LDL, Homocysteine and Nitric Oxide as Clinical Parameters of Oxidative Stress and Endothelial Dysfunction. in Current Analytical Chemistry. 2022;18(10):1040-1056.
doi:10.2174/1573411018666220827142613 .
Mačvanin, Mirjana, Stanimirović, Julijana, Isenović, Esma R., "Methods for Measurements of Oxidized LDL, Homocysteine and Nitric Oxide as Clinical Parameters of Oxidative Stress and Endothelial Dysfunction" in Current Analytical Chemistry, 18, no. 10 (2022):1040-1056,
https://doi.org/10.2174/1573411018666220827142613 . .
3
1

Role of C-Reactive Protein in Diabetic Inflammation

Stanimirović, Julijana; Radovanović, Jelena; Banjac, Katarina; Obradović, Milan M.; Essack, Magbubah; Zafirović, Sonja; Gluvić, Zoran; Gojobori, Takashi; Isenović, Esma R.

(2022)

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Radovanović, Jelena
AU  - Banjac, Katarina
AU  - Obradović, Milan M.
AU  - Essack, Magbubah
AU  - Zafirović, Sonja
AU  - Gluvić, Zoran
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10285
AB  - Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.
T2  - Mediators of Inflammation
T1  - Role of C-Reactive Protein in Diabetic Inflammation
VL  - 2022
SP  - e3706508
DO  - 10.1155/2022/3706508
ER  - 
@article{
author = "Stanimirović, Julijana and Radovanović, Jelena and Banjac, Katarina and Obradović, Milan M. and Essack, Magbubah and Zafirović, Sonja and Gluvić, Zoran and Gojobori, Takashi and Isenović, Esma R.",
year = "2022",
abstract = "Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.",
journal = "Mediators of Inflammation",
title = "Role of C-Reactive Protein in Diabetic Inflammation",
volume = "2022",
pages = "e3706508",
doi = "10.1155/2022/3706508"
}
Stanimirović, J., Radovanović, J., Banjac, K., Obradović, M. M., Essack, M., Zafirović, S., Gluvić, Z., Gojobori, T.,& Isenović, E. R.. (2022). Role of C-Reactive Protein in Diabetic Inflammation. in Mediators of Inflammation, 2022, e3706508.
https://doi.org/10.1155/2022/3706508
Stanimirović J, Radovanović J, Banjac K, Obradović MM, Essack M, Zafirović S, Gluvić Z, Gojobori T, Isenović ER. Role of C-Reactive Protein in Diabetic Inflammation. in Mediators of Inflammation. 2022;2022:e3706508.
doi:10.1155/2022/3706508 .
Stanimirović, Julijana, Radovanović, Jelena, Banjac, Katarina, Obradović, Milan M., Essack, Magbubah, Zafirović, Sonja, Gluvić, Zoran, Gojobori, Takashi, Isenović, Esma R., "Role of C-Reactive Protein in Diabetic Inflammation" in Mediators of Inflammation, 2022 (2022):e3706508,
https://doi.org/10.1155/2022/3706508 . .
22
18

Redox control of vascular biology

Obradović, Milan M.; Essack, Magbubah; Zafirović, Sonja; Sudar-Milovanović, Emina; Bajić, Vladan P.; Van Neste, Christophe; Trpković, Andreja; Stanimirović, Julijana; Bajić, Vladimir B.; Isenović, Esma R.

(2020)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Essack, Magbubah
AU  - Zafirović, Sonja
AU  - Sudar-Milovanović, Emina
AU  - Bajić, Vladan P.
AU  - Van Neste, Christophe
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Bajić, Vladimir B.
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8486
AB  - Redox control is lost when the antioxidant defense system cannot remove abnormally high concentrations of signaling molecules, such as reactive oxygen species (ROS). Chronically elevated levels of ROS cause oxidative stress that may eventually lead to cancer and cardiovascular and neurodegenerative diseases. In this review, we focus on redox effects in the vascular system. We pay close attention to the subcompartments of the vascular system (endothelium, smooth muscle cell layer) and give an overview of how redox changes influence those different compartments. We also review the core aspects of redox biology, cardiovascular physiology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-RedoxVasc was used to develop two case studies, one focused on endothelial cells and the other on the vascular smooth muscle cells, as a starting point to possibly extend our knowledge of redox control in vascular biology. © 2019 The Authors. BioFactors published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology.
T2  - BioFactors
T1  - Redox control of vascular biology
VL  - 46
IS  - 2
SP  - 246
EP  - 262
DO  - 10.1002/biof.1559
ER  - 
@article{
author = "Obradović, Milan M. and Essack, Magbubah and Zafirović, Sonja and Sudar-Milovanović, Emina and Bajić, Vladan P. and Van Neste, Christophe and Trpković, Andreja and Stanimirović, Julijana and Bajić, Vladimir B. and Isenović, Esma R.",
year = "2020",
abstract = "Redox control is lost when the antioxidant defense system cannot remove abnormally high concentrations of signaling molecules, such as reactive oxygen species (ROS). Chronically elevated levels of ROS cause oxidative stress that may eventually lead to cancer and cardiovascular and neurodegenerative diseases. In this review, we focus on redox effects in the vascular system. We pay close attention to the subcompartments of the vascular system (endothelium, smooth muscle cell layer) and give an overview of how redox changes influence those different compartments. We also review the core aspects of redox biology, cardiovascular physiology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-RedoxVasc was used to develop two case studies, one focused on endothelial cells and the other on the vascular smooth muscle cells, as a starting point to possibly extend our knowledge of redox control in vascular biology. © 2019 The Authors. BioFactors published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology.",
journal = "BioFactors",
title = "Redox control of vascular biology",
volume = "46",
number = "2",
pages = "246-262",
doi = "10.1002/biof.1559"
}
Obradović, M. M., Essack, M., Zafirović, S., Sudar-Milovanović, E., Bajić, V. P., Van Neste, C., Trpković, A., Stanimirović, J., Bajić, V. B.,& Isenović, E. R.. (2020). Redox control of vascular biology. in BioFactors, 46(2), 246-262.
https://doi.org/10.1002/biof.1559
Obradović MM, Essack M, Zafirović S, Sudar-Milovanović E, Bajić VP, Van Neste C, Trpković A, Stanimirović J, Bajić VB, Isenović ER. Redox control of vascular biology. in BioFactors. 2020;46(2):246-262.
doi:10.1002/biof.1559 .
Obradović, Milan M., Essack, Magbubah, Zafirović, Sonja, Sudar-Milovanović, Emina, Bajić, Vladan P., Van Neste, Christophe, Trpković, Andreja, Stanimirović, Julijana, Bajić, Vladimir B., Isenović, Esma R., "Redox control of vascular biology" in BioFactors, 46, no. 2 (2020):246-262,
https://doi.org/10.1002/biof.1559 . .
2
15
10
14

Hypothesis related to the regulation of inducible nitric oxide synthase during carotid endarterectomy

Obradović, Milan M.; Bogdanović, Nikola; Stanimirović, Julijana; Unić-Stojanović, Dragana R.; Radak, Đorđe J.; Isenović, Esma R.

(2019)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Bogdanović, Nikola
AU  - Stanimirović, Julijana
AU  - Unić-Stojanović, Dragana R.
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0306987718308302
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7930
AB  - Sudden occlusion of an artery caused by a thrombus or emboli is the most frequent cause of acute brain ischemia (ABI). Carotid endarterectomy (CEA) represents the gold standard for preventing strokes of carotid origin. However, neuronal damage caused by ischemia and/or reperfusion may contribute to a poor clinical outcome after CEA. In response to shear stress caused by hypoxic-ischemic conditions in patients undergoing CEA, stimulation of the hypothalamic-pituitaryadrenal axis leads to biological responses known as hypermetabolic stress, characterized by hemodynamic, metabolic, inflammatory and immunological changes. These changes maintain homeostasis and assist recovery, but an unregulated inflammatory response could lead to further tissue damage and death of neurons. Nitric oxide (NO) is an important signaling molecule involved in several physiological and pathological processes, including ABI. However, an excess of NO could have detrimental effects. We hypothesized that the hypoxic-ischemic state induced by carotid clamping leads to overexpression of inducible NO synthase and that uncontrolled production of NO could adversely affect outcome after CEA. © 2018 Elsevier Ltd
T2  - Medical Hypotheses
T1  - Hypothesis related to the regulation of inducible nitric oxide synthase during carotid endarterectomy
VL  - 122
SP  - 16
EP  - 18
DO  - 10.1016/j.mehy.2018.10.011
ER  - 
@article{
author = "Obradović, Milan M. and Bogdanović, Nikola and Stanimirović, Julijana and Unić-Stojanović, Dragana R. and Radak, Đorđe J. and Isenović, Esma R.",
year = "2019",
abstract = "Sudden occlusion of an artery caused by a thrombus or emboli is the most frequent cause of acute brain ischemia (ABI). Carotid endarterectomy (CEA) represents the gold standard for preventing strokes of carotid origin. However, neuronal damage caused by ischemia and/or reperfusion may contribute to a poor clinical outcome after CEA. In response to shear stress caused by hypoxic-ischemic conditions in patients undergoing CEA, stimulation of the hypothalamic-pituitaryadrenal axis leads to biological responses known as hypermetabolic stress, characterized by hemodynamic, metabolic, inflammatory and immunological changes. These changes maintain homeostasis and assist recovery, but an unregulated inflammatory response could lead to further tissue damage and death of neurons. Nitric oxide (NO) is an important signaling molecule involved in several physiological and pathological processes, including ABI. However, an excess of NO could have detrimental effects. We hypothesized that the hypoxic-ischemic state induced by carotid clamping leads to overexpression of inducible NO synthase and that uncontrolled production of NO could adversely affect outcome after CEA. © 2018 Elsevier Ltd",
journal = "Medical Hypotheses",
title = "Hypothesis related to the regulation of inducible nitric oxide synthase during carotid endarterectomy",
volume = "122",
pages = "16-18",
doi = "10.1016/j.mehy.2018.10.011"
}
Obradović, M. M., Bogdanović, N., Stanimirović, J., Unić-Stojanović, D. R., Radak, Đ. J.,& Isenović, E. R.. (2019). Hypothesis related to the regulation of inducible nitric oxide synthase during carotid endarterectomy. in Medical Hypotheses, 122, 16-18.
https://doi.org/10.1016/j.mehy.2018.10.011
Obradović MM, Bogdanović N, Stanimirović J, Unić-Stojanović DR, Radak ĐJ, Isenović ER. Hypothesis related to the regulation of inducible nitric oxide synthase during carotid endarterectomy. in Medical Hypotheses. 2019;122:16-18.
doi:10.1016/j.mehy.2018.10.011 .
Obradović, Milan M., Bogdanović, Nikola, Stanimirović, Julijana, Unić-Stojanović, Dragana R., Radak, Đorđe J., Isenović, Esma R., "Hypothesis related to the regulation of inducible nitric oxide synthase during carotid endarterectomy" in Medical Hypotheses, 122 (2019):16-18,
https://doi.org/10.1016/j.mehy.2018.10.011 . .
2
4
1
2

Effects of IGF-1 on the cardiovascular system

Obradović, Milan M.; Zafirović, Sonja; Soskić, Sanja S.; Stanimirović, Julijana; Trpković, Andreja; Jevremović, Danimir P.; Isenović, Esma R.

(2019)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Soskić, Sanja S.
AU  - Stanimirović, Julijana
AU  - Trpković, Andreja
AU  - Jevremović, Danimir P.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8483
AB  - Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.
T2  - Current Pharmaceutical Design
T1  - Effects of IGF-1 on the cardiovascular system
VL  - 25
IS  - 35
SP  - 3715
EP  - 3725
DO  - 10.2174/1381612825666191106091507
ER  - 
@article{
author = "Obradović, Milan M. and Zafirović, Sonja and Soskić, Sanja S. and Stanimirović, Julijana and Trpković, Andreja and Jevremović, Danimir P. and Isenović, Esma R.",
year = "2019",
abstract = "Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.",
journal = "Current Pharmaceutical Design",
title = "Effects of IGF-1 on the cardiovascular system",
volume = "25",
number = "35",
pages = "3715-3725",
doi = "10.2174/1381612825666191106091507"
}
Obradović, M. M., Zafirović, S., Soskić, S. S., Stanimirović, J., Trpković, A., Jevremović, D. P.,& Isenović, E. R.. (2019). Effects of IGF-1 on the cardiovascular system. in Current Pharmaceutical Design, 25(35), 3715-3725.
https://doi.org/10.2174/1381612825666191106091507
Obradović MM, Zafirović S, Soskić SS, Stanimirović J, Trpković A, Jevremović DP, Isenović ER. Effects of IGF-1 on the cardiovascular system. in Current Pharmaceutical Design. 2019;25(35):3715-3725.
doi:10.2174/1381612825666191106091507 .
Obradović, Milan M., Zafirović, Sonja, Soskić, Sanja S., Stanimirović, Julijana, Trpković, Andreja, Jevremović, Danimir P., Isenović, Esma R., "Effects of IGF-1 on the cardiovascular system" in Current Pharmaceutical Design, 25, no. 35 (2019):3715-3725,
https://doi.org/10.2174/1381612825666191106091507 . .
23
8
20

Literature-Based Enrichment Insights into Redox Control of Vascular Biology

Essack, Magbubah; Salhi, Adil; Stanimirović, Julijana; Tifratene, Faroug; Bin Raies, Arwa; Hungler, Arnaud; Uludag, Mahmut; Van Neste, Christophe; Trpković, Andreja; Bajić, Vladan P.; Bajić, Vladimir B.; Isenović, Esma R.

(2019)

TY  - JOUR
AU  - Essack, Magbubah
AU  - Salhi, Adil
AU  - Stanimirović, Julijana
AU  - Tifratene, Faroug
AU  - Bin Raies, Arwa
AU  - Hungler, Arnaud
AU  - Uludag, Mahmut
AU  - Van Neste, Christophe
AU  - Trpković, Andreja
AU  - Bajić, Vladan P.
AU  - Bajić, Vladimir B.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8389
AB  - In cellular physiology and signaling, reactive oxygen species (ROS) play one of the most critical roles. ROS overproduction leads to cellular oxidative stress. This may lead to an irrecoverable imbalance of redox (oxidation-reduction reaction) function that deregulates redox homeostasis, which itself could lead to several diseases including neurodegenerative disease, cardiovascular disease, and cancers. In this study, we focus on the redox effects related to vascular systems in mammals. To support research in this domain, we developed an online knowledge base, DES-RedoxVasc, which enables exploration of information contained in the biomedical scientific literature. The DES-RedoxVasc system analyzed 233399 documents consisting of PubMed abstracts and PubMed Central full-text articles related to different aspects of redox biology in vascular systems. It allows researchers to explore enriched concepts from 28 curated thematic dictionaries, as well as literature-derived potential associations of pairs of such enriched concepts, where associations themselves are statistically enriched. For example, the system allows exploration of associations of pathways, diseases, mutations, genes/proteins, miRNAs, long ncRNAs, toxins, drugs, biological processes, molecular functions, etc. that allow for insights about different aspects of redox effects and control of processes related to the vascular system. Moreover, we deliver case studies about some existing or possibly novel knowledge regarding redox of vascular biology demonstrating the usefulness of DES-RedoxVasc. DES-RedoxVasc is the first compiled knowledge base using text mining for the exploration of this topic.
T2  - Oxidative Medicine and Cellular Longevity
T1  - Literature-Based Enrichment Insights into Redox Control of Vascular Biology
VL  - 2019
SP  - 1769437
DO  - 10.1155/2019/1769437
ER  - 
@article{
author = "Essack, Magbubah and Salhi, Adil and Stanimirović, Julijana and Tifratene, Faroug and Bin Raies, Arwa and Hungler, Arnaud and Uludag, Mahmut and Van Neste, Christophe and Trpković, Andreja and Bajić, Vladan P. and Bajić, Vladimir B. and Isenović, Esma R.",
year = "2019",
abstract = "In cellular physiology and signaling, reactive oxygen species (ROS) play one of the most critical roles. ROS overproduction leads to cellular oxidative stress. This may lead to an irrecoverable imbalance of redox (oxidation-reduction reaction) function that deregulates redox homeostasis, which itself could lead to several diseases including neurodegenerative disease, cardiovascular disease, and cancers. In this study, we focus on the redox effects related to vascular systems in mammals. To support research in this domain, we developed an online knowledge base, DES-RedoxVasc, which enables exploration of information contained in the biomedical scientific literature. The DES-RedoxVasc system analyzed 233399 documents consisting of PubMed abstracts and PubMed Central full-text articles related to different aspects of redox biology in vascular systems. It allows researchers to explore enriched concepts from 28 curated thematic dictionaries, as well as literature-derived potential associations of pairs of such enriched concepts, where associations themselves are statistically enriched. For example, the system allows exploration of associations of pathways, diseases, mutations, genes/proteins, miRNAs, long ncRNAs, toxins, drugs, biological processes, molecular functions, etc. that allow for insights about different aspects of redox effects and control of processes related to the vascular system. Moreover, we deliver case studies about some existing or possibly novel knowledge regarding redox of vascular biology demonstrating the usefulness of DES-RedoxVasc. DES-RedoxVasc is the first compiled knowledge base using text mining for the exploration of this topic.",
journal = "Oxidative Medicine and Cellular Longevity",
title = "Literature-Based Enrichment Insights into Redox Control of Vascular Biology",
volume = "2019",
pages = "1769437",
doi = "10.1155/2019/1769437"
}
Essack, M., Salhi, A., Stanimirović, J., Tifratene, F., Bin Raies, A., Hungler, A., Uludag, M., Van Neste, C., Trpković, A., Bajić, V. P., Bajić, V. B.,& Isenović, E. R.. (2019). Literature-Based Enrichment Insights into Redox Control of Vascular Biology. in Oxidative Medicine and Cellular Longevity, 2019, 1769437.
https://doi.org/10.1155/2019/1769437
Essack M, Salhi A, Stanimirović J, Tifratene F, Bin Raies A, Hungler A, Uludag M, Van Neste C, Trpković A, Bajić VP, Bajić VB, Isenović ER. Literature-Based Enrichment Insights into Redox Control of Vascular Biology. in Oxidative Medicine and Cellular Longevity. 2019;2019:1769437.
doi:10.1155/2019/1769437 .
Essack, Magbubah, Salhi, Adil, Stanimirović, Julijana, Tifratene, Faroug, Bin Raies, Arwa, Hungler, Arnaud, Uludag, Mahmut, Van Neste, Christophe, Trpković, Andreja, Bajić, Vladan P., Bajić, Vladimir B., Isenović, Esma R., "Literature-Based Enrichment Insights into Redox Control of Vascular Biology" in Oxidative Medicine and Cellular Longevity, 2019 (2019):1769437,
https://doi.org/10.1155/2019/1769437 . .
8
3
8

17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis

Panić, Anastasija; Stanimirović, Julijana; Obradović, Milan M.; Zafirović, Sonja; Sudar-Milovanović, Emina; Petrović, Nina; Isenović, Esma R.

(2018)

TY  - JOUR
AU  - Panić, Anastasija
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Sudar-Milovanović, Emina
AU  - Petrović, Nina
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8013
AB  - 17β-Estradiol (E2) is known to negatively regulate inducible nitric oxide (NO) synthase (iNOS) expression via estrogen receptor alpha (ER-α) activation in aortic vascular smooth muscle cells.Therefore, we sought to determine whether E2 can inhibit iNOS in vivo in hepatic tissue via the activation of ER-α and whether extracellular signal-regulated kinases 1/2 (ERK1/2)-miR-221 axis is involved in this process. Male Wistar rats were treated with a bolus injection of E2 intraperitoneally (40 μg/kg), and 24 hours after treatment the animals were sacrificed and the livers excised. The protein levels of iNOS, p50 and p65 subunits of nuclear factor κB (NFκB), ERα, ERK1/2 and protein kinase B (Akt), as well as the association of ERα/Src in liver lysates were assessed by Western blot. The expression of hepatic miR-221 was analyzed by qRT-PCR. Results show that E2 reduced hepatic iNOS protein expression (p less than 0.01), the protein level of ERα (p less than 0.05), ERK1/2 (p less than 0.05), Akt phosphorylation (p less than 0.001) and miR-221 expression (p less than 0.05). In contrast, hepatic ERα/Src kinase association level (p less than 0.05) increased after E2 treatment. Our results indicate that E2 inhibits hepatic iNOS via molecular mechanisms involving the activation of the ER-α and inhibition of ERK1/2-miR-221 axis.
T2  - Journal of biological regulators and homeostatic agents
T1  - 17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis
VL  - 32
IS  - 6
SP  - 1369
EP  - 1377
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8013
ER  - 
@article{
author = "Panić, Anastasija and Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Sudar-Milovanović, Emina and Petrović, Nina and Isenović, Esma R.",
year = "2018",
abstract = "17β-Estradiol (E2) is known to negatively regulate inducible nitric oxide (NO) synthase (iNOS) expression via estrogen receptor alpha (ER-α) activation in aortic vascular smooth muscle cells.Therefore, we sought to determine whether E2 can inhibit iNOS in vivo in hepatic tissue via the activation of ER-α and whether extracellular signal-regulated kinases 1/2 (ERK1/2)-miR-221 axis is involved in this process. Male Wistar rats were treated with a bolus injection of E2 intraperitoneally (40 μg/kg), and 24 hours after treatment the animals were sacrificed and the livers excised. The protein levels of iNOS, p50 and p65 subunits of nuclear factor κB (NFκB), ERα, ERK1/2 and protein kinase B (Akt), as well as the association of ERα/Src in liver lysates were assessed by Western blot. The expression of hepatic miR-221 was analyzed by qRT-PCR. Results show that E2 reduced hepatic iNOS protein expression (p less than 0.01), the protein level of ERα (p less than 0.05), ERK1/2 (p less than 0.05), Akt phosphorylation (p less than 0.001) and miR-221 expression (p less than 0.05). In contrast, hepatic ERα/Src kinase association level (p less than 0.05) increased after E2 treatment. Our results indicate that E2 inhibits hepatic iNOS via molecular mechanisms involving the activation of the ER-α and inhibition of ERK1/2-miR-221 axis.",
journal = "Journal of biological regulators and homeostatic agents",
title = "17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis",
volume = "32",
number = "6",
pages = "1369-1377",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8013"
}
Panić, A., Stanimirović, J., Obradović, M. M., Zafirović, S., Sudar-Milovanović, E., Petrović, N.,& Isenović, E. R.. (2018). 17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis. in Journal of biological regulators and homeostatic agents, 32(6), 1369-1377.
https://hdl.handle.net/21.15107/rcub_vinar_8013
Panić A, Stanimirović J, Obradović MM, Zafirović S, Sudar-Milovanović E, Petrović N, Isenović ER. 17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis. in Journal of biological regulators and homeostatic agents. 2018;32(6):1369-1377.
https://hdl.handle.net/21.15107/rcub_vinar_8013 .
Panić, Anastasija, Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Sudar-Milovanović, Emina, Petrović, Nina, Isenović, Esma R., "17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis" in Journal of biological regulators and homeostatic agents, 32, no. 6 (2018):1369-1377,
https://hdl.handle.net/21.15107/rcub_vinar_8013 .
4

Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221

Panić, Anastasija; Stanimirović, Julijana; Obradović, Milan M.; Sudar-Milovanović, Emina; Perović, Milan; Lačković, Milena; Petrović, Nina; Isenović, Esma R.

(2018)

TY  - JOUR
AU  - Panić, Anastasija
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Perović, Milan
AU  - Lačković, Milena
AU  - Petrović, Nina
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8399
AB  - Purpose: This study aimed to investigate in vivo effects of estradiol on the regulation of hepatic inducible nitric oxide synthase (iNOS) expression in the high fat (HF) diet-induced obesity. Also, we aimed to investigate whether activation of the extracellular signal-regulated kinase (ERK1/2), adenosine monophosphate-activated protein kinase (AMPK), Src kinase, and miR-221 is involved in estradiol-mediated regulation of iNOS in the liver of obese male Wistar rats. Male Wistar rats were fed a standard laboratory diet or a HF diet for 10 weeks. Half of HF rats were treated with estradiol intraperitoneally (40 μg/kg), whereas the other half were placebo-treated 24 H before euthanasia. Results show that estradiol treatment of HF rats decreased hepatic iNOS mRNA (P < 0.05) and protein expression (P < 0.01), the protein levels of p65 subunit of nuclear factor κB (P < 0.05) and ERα (P < 0.05), ERK1/2 phosphorylation (P < 0.001), and ERα/Src kinase association (P < 0.05). By contrast, hepatic Src protein level (P < 0.05), AMPKα phosphorylation (P < 0.05), and miR-221 expression (P < 0.05) were increased in HF rats after estradiol treatment. Our results indicate that estradiol in vivo regulates hepatic iNOS expression in obese rats via molecular mechanisms involving ERK1/2, AMPK, Src, and miR-221 signaling. © 2018 International Union of Biochemistry and Molecular Biology, Inc.
T2  - Biotechnology and Applied Biochemistry
T1  - Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221
VL  - 65
IS  - 6
SP  - 797
EP  - 806
DO  - 10.1002/bab.1680
ER  - 
@article{
author = "Panić, Anastasija and Stanimirović, Julijana and Obradović, Milan M. and Sudar-Milovanović, Emina and Perović, Milan and Lačković, Milena and Petrović, Nina and Isenović, Esma R.",
year = "2018",
abstract = "Purpose: This study aimed to investigate in vivo effects of estradiol on the regulation of hepatic inducible nitric oxide synthase (iNOS) expression in the high fat (HF) diet-induced obesity. Also, we aimed to investigate whether activation of the extracellular signal-regulated kinase (ERK1/2), adenosine monophosphate-activated protein kinase (AMPK), Src kinase, and miR-221 is involved in estradiol-mediated regulation of iNOS in the liver of obese male Wistar rats. Male Wistar rats were fed a standard laboratory diet or a HF diet for 10 weeks. Half of HF rats were treated with estradiol intraperitoneally (40 μg/kg), whereas the other half were placebo-treated 24 H before euthanasia. Results show that estradiol treatment of HF rats decreased hepatic iNOS mRNA (P < 0.05) and protein expression (P < 0.01), the protein levels of p65 subunit of nuclear factor κB (P < 0.05) and ERα (P < 0.05), ERK1/2 phosphorylation (P < 0.001), and ERα/Src kinase association (P < 0.05). By contrast, hepatic Src protein level (P < 0.05), AMPKα phosphorylation (P < 0.05), and miR-221 expression (P < 0.05) were increased in HF rats after estradiol treatment. Our results indicate that estradiol in vivo regulates hepatic iNOS expression in obese rats via molecular mechanisms involving ERK1/2, AMPK, Src, and miR-221 signaling. © 2018 International Union of Biochemistry and Molecular Biology, Inc.",
journal = "Biotechnology and Applied Biochemistry",
title = "Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221",
volume = "65",
number = "6",
pages = "797-806",
doi = "10.1002/bab.1680"
}
Panić, A., Stanimirović, J., Obradović, M. M., Sudar-Milovanović, E., Perović, M., Lačković, M., Petrović, N.,& Isenović, E. R.. (2018). Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221. in Biotechnology and Applied Biochemistry, 65(6), 797-806.
https://doi.org/10.1002/bab.1680
Panić A, Stanimirović J, Obradović MM, Sudar-Milovanović E, Perović M, Lačković M, Petrović N, Isenović ER. Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221. in Biotechnology and Applied Biochemistry. 2018;65(6):797-806.
doi:10.1002/bab.1680 .
Panić, Anastasija, Stanimirović, Julijana, Obradović, Milan M., Sudar-Milovanović, Emina, Perović, Milan, Lačković, Milena, Petrović, Nina, Isenović, Esma R., "Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221" in Biotechnology and Applied Biochemistry, 65, no. 6 (2018):797-806,
https://doi.org/10.1002/bab.1680 . .
8
4
6

Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti

Stanimirović, Julijana; Obradović, Milan M.; Gluvić, Zoran; Isenović, Esma R.

(2018)

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10154
AB  - Jetra ima važnu ulogu u održavanju metaboličke homeostaze i predstavlja mesto kompleksne regulacije metabolizma supstrata (ugljenih hidrata, lipida i proteina) od strane insulina i drugih hormona. Proteklih decenija ističe se značaj metaboličkih funkcija jetre u brojnim patološkim stanjima. Mehanizmi kojima gojaznost dovodi do poremećaja metaboličkih procesa u jetri su danas predmet mnogobrojnih istraživanja. Metaboličke i hormonske promene koje su posledica prevashodno visceralne gojaznosti, dovode vremenom do nagomilavanja lipida u jetri. Povećana učestalost gojaznosti i razvoj metaboličkog sindroma doprinose pojavi patofizioloških promena u jetri i razvoju nealkoholne bolesti masne jetre (NAFLD), jednoj od najčešćih bolesti jetre u zapadnoevropskim zemljama. U ovom preglednom članku razmotrili smo najnovije literaturne podatke koji se odnose na ulogu jetre u metabolizmu glukoze i lipida u stanju gojaznosti.
AB  - The liver plays a vital role in metabolic homeostasis and represents a major site for complex regulation of substrates (carbohydrates, lipids, and proteins) by insulin and other hormones. The significance of liver metabolic functions in many pathophysiological conditions is highlighted over the past decades. Mechanisms of obesity-induced metabolic disturbance in the liver are the topic of numerous research studies. Metabolic and hormonal changes which are caused primarily by visceral obesity lead to hepatic lipid accumulation. Increased prevalence of obesity and the development of metabolic syndrome contribute to pathophysiological changes in the liver and development of non-alcoholic fatty liver disease (NAFLD), one of the most common diseases in Western societies. In this review, we discussed most recent literature data related to the role of the liver in glucose and lipid metabolism in obesity.
T2  - Medicinska istraživanja
T1  - Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti
T1  - The role of the liver in glucose and lipid metabolism in obesity
VL  - 52
IS  - 3
SP  - 1
EP  - 6
DO  - 10.5937/MedIst1803001S
ER  - 
@article{
author = "Stanimirović, Julijana and Obradović, Milan M. and Gluvić, Zoran and Isenović, Esma R.",
year = "2018",
abstract = "Jetra ima važnu ulogu u održavanju metaboličke homeostaze i predstavlja mesto kompleksne regulacije metabolizma supstrata (ugljenih hidrata, lipida i proteina) od strane insulina i drugih hormona. Proteklih decenija ističe se značaj metaboličkih funkcija jetre u brojnim patološkim stanjima. Mehanizmi kojima gojaznost dovodi do poremećaja metaboličkih procesa u jetri su danas predmet mnogobrojnih istraživanja. Metaboličke i hormonske promene koje su posledica prevashodno visceralne gojaznosti, dovode vremenom do nagomilavanja lipida u jetri. Povećana učestalost gojaznosti i razvoj metaboličkog sindroma doprinose pojavi patofizioloških promena u jetri i razvoju nealkoholne bolesti masne jetre (NAFLD), jednoj od najčešćih bolesti jetre u zapadnoevropskim zemljama. U ovom preglednom članku razmotrili smo najnovije literaturne podatke koji se odnose na ulogu jetre u metabolizmu glukoze i lipida u stanju gojaznosti., The liver plays a vital role in metabolic homeostasis and represents a major site for complex regulation of substrates (carbohydrates, lipids, and proteins) by insulin and other hormones. The significance of liver metabolic functions in many pathophysiological conditions is highlighted over the past decades. Mechanisms of obesity-induced metabolic disturbance in the liver are the topic of numerous research studies. Metabolic and hormonal changes which are caused primarily by visceral obesity lead to hepatic lipid accumulation. Increased prevalence of obesity and the development of metabolic syndrome contribute to pathophysiological changes in the liver and development of non-alcoholic fatty liver disease (NAFLD), one of the most common diseases in Western societies. In this review, we discussed most recent literature data related to the role of the liver in glucose and lipid metabolism in obesity.",
journal = "Medicinska istraživanja",
title = "Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti, The role of the liver in glucose and lipid metabolism in obesity",
volume = "52",
number = "3",
pages = "1-6",
doi = "10.5937/MedIst1803001S"
}
Stanimirović, J., Obradović, M. M., Gluvić, Z.,& Isenović, E. R.. (2018). Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti. in Medicinska istraživanja, 52(3), 1-6.
https://doi.org/10.5937/MedIst1803001S
Stanimirović J, Obradović MM, Gluvić Z, Isenović ER. Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti. in Medicinska istraživanja. 2018;52(3):1-6.
doi:10.5937/MedIst1803001S .
Stanimirović, Julijana, Obradović, Milan M., Gluvić, Zoran, Isenović, Esma R., "Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti" in Medicinska istraživanja, 52, no. 3 (2018):1-6,
https://doi.org/10.5937/MedIst1803001S . .

IGF-1 ameliorates detrimental effects of obesity in rat heart by promoting akt and FOXO1

Stanimirović, Julijana; Panić, Anastasija; Obradović, Milan M.; Zafirović, Sonja; Isenović, Esma R.

(2018)

TY  - CONF
AU  - Stanimirović, Julijana
AU  - Panić, Anastasija
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0021915018307147
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7948
C3  - Atherosclerosis
T1  - IGF-1 ameliorates detrimental effects of obesity in rat heart by promoting akt and FOXO1
VL  - 275
SP  - e137
DO  - 10.1016/j.atherosclerosis.2018.06.402
ER  - 
@conference{
author = "Stanimirović, Julijana and Panić, Anastasija and Obradović, Milan M. and Zafirović, Sonja and Isenović, Esma R.",
year = "2018",
journal = "Atherosclerosis",
title = "IGF-1 ameliorates detrimental effects of obesity in rat heart by promoting akt and FOXO1",
volume = "275",
pages = "e137",
doi = "10.1016/j.atherosclerosis.2018.06.402"
}
Stanimirović, J., Panić, A., Obradović, M. M., Zafirović, S.,& Isenović, E. R.. (2018). IGF-1 ameliorates detrimental effects of obesity in rat heart by promoting akt and FOXO1. in Atherosclerosis, 275, e137.
https://doi.org/10.1016/j.atherosclerosis.2018.06.402
Stanimirović J, Panić A, Obradović MM, Zafirović S, Isenović ER. IGF-1 ameliorates detrimental effects of obesity in rat heart by promoting akt and FOXO1. in Atherosclerosis. 2018;275:e137.
doi:10.1016/j.atherosclerosis.2018.06.402 .
Stanimirović, Julijana, Panić, Anastasija, Obradović, Milan M., Zafirović, Sonja, Isenović, Esma R., "IGF-1 ameliorates detrimental effects of obesity in rat heart by promoting akt and FOXO1" in Atherosclerosis, 275 (2018):e137,
https://doi.org/10.1016/j.atherosclerosis.2018.06.402 . .

Regulation of hepatic Na+/K+-ATPase in obese female and male rats: involvement of ERK1/2, AMPK, and Rho/ROCK

(2018)

TY  - JOUR
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7581
AB  - In this study, we assessed whether the disturbed regulation of sodium/potassium-adenosine-triphosphatase (Na+/K+-ATPase) occurs as a consequence of obesity-induced IR in sex-specific manner. We also assessed whether alterations of IRS/PI3K/Akt, ERK1/2, AMPK alpha, and RhoA/ROCK signaling cascades have an important role in this pathology. Female and male Wistar rats (150-200 g, 8 weeks old) were fed a standard laboratory diet or a high-fat (HF) diet (42% fat) for 10 weeks. The activity of hepatic Na+/K+-ATPase and Rho, and the association of IRS-1/p85 were assessed in liver. Furthermore, the protein level of alpha(1) Na+/K+-ATPase in plasma membrane fractions, and protein levels of IRS-1, PI3K-p85, -p110, RhoA, ROCK1, ROCK2, ERK1/2, AMPK alpha, ER alpha, and ER beta in liver lysates were assessed. The expression of hepatic alpha(1) Na+/K+-ATPase mRNA was also analyzed by qRT-PCR. The results show that HF-fed female rats exhibited an increase in hepatic ERK1/2 (p < 0.05) and AMPK alpha (p < 0.05) phosphorylation levels, unchanged level of Na+/K+-ATPase alpha(1) mRNA, decreased level of Na+/K+-ATPase activity (p < 0.05), and decreased alpha(1) Na+/K+-ATPase protein expression (p < 0.01). In liver of HF-fed male rats, results show decreased levels of Na+/K+-ATPase activity (p < 0.01), both protein and mRNA of alpha(1) subunit (p < 0.05), but significant increase in Rho activity (p < 0.05). Our results indicate significant sex differences in alpha(1) Na+/K+-ATPase mRNA expression and activation of ERK1/2, AMPK alpha, and Rho in the liver. Exploring the sex-specific factors and pathways that promote obesity-related diseases may lead to a better understanding of pathogenesis and discovering new therapeutic targets.
T2  - Molecular and Cellular Biochemistry
T1  - Regulation of hepatic Na+/K+-ATPase in obese female and male rats: involvement of ERK1/2, AMPK, and Rho/ROCK
VL  - 440
SP  - 77
EP  - 88
DO  - 10.1007/s11010-017-3157-z
ER  - 
@article{
year = "2018",
abstract = "In this study, we assessed whether the disturbed regulation of sodium/potassium-adenosine-triphosphatase (Na+/K+-ATPase) occurs as a consequence of obesity-induced IR in sex-specific manner. We also assessed whether alterations of IRS/PI3K/Akt, ERK1/2, AMPK alpha, and RhoA/ROCK signaling cascades have an important role in this pathology. Female and male Wistar rats (150-200 g, 8 weeks old) were fed a standard laboratory diet or a high-fat (HF) diet (42% fat) for 10 weeks. The activity of hepatic Na+/K+-ATPase and Rho, and the association of IRS-1/p85 were assessed in liver. Furthermore, the protein level of alpha(1) Na+/K+-ATPase in plasma membrane fractions, and protein levels of IRS-1, PI3K-p85, -p110, RhoA, ROCK1, ROCK2, ERK1/2, AMPK alpha, ER alpha, and ER beta in liver lysates were assessed. The expression of hepatic alpha(1) Na+/K+-ATPase mRNA was also analyzed by qRT-PCR. The results show that HF-fed female rats exhibited an increase in hepatic ERK1/2 (p < 0.05) and AMPK alpha (p < 0.05) phosphorylation levels, unchanged level of Na+/K+-ATPase alpha(1) mRNA, decreased level of Na+/K+-ATPase activity (p < 0.05), and decreased alpha(1) Na+/K+-ATPase protein expression (p < 0.01). In liver of HF-fed male rats, results show decreased levels of Na+/K+-ATPase activity (p < 0.01), both protein and mRNA of alpha(1) subunit (p < 0.05), but significant increase in Rho activity (p < 0.05). Our results indicate significant sex differences in alpha(1) Na+/K+-ATPase mRNA expression and activation of ERK1/2, AMPK alpha, and Rho in the liver. Exploring the sex-specific factors and pathways that promote obesity-related diseases may lead to a better understanding of pathogenesis and discovering new therapeutic targets.",
journal = "Molecular and Cellular Biochemistry",
title = "Regulation of hepatic Na+/K+-ATPase in obese female and male rats: involvement of ERK1/2, AMPK, and Rho/ROCK",
volume = "440",
pages = "77-88",
doi = "10.1007/s11010-017-3157-z"
}
(2018). Regulation of hepatic Na+/K+-ATPase in obese female and male rats: involvement of ERK1/2, AMPK, and Rho/ROCK. in Molecular and Cellular Biochemistry, 440, 77-88.
https://doi.org/10.1007/s11010-017-3157-z
Regulation of hepatic Na+/K+-ATPase in obese female and male rats: involvement of ERK1/2, AMPK, and Rho/ROCK. in Molecular and Cellular Biochemistry. 2018;440:77-88.
doi:10.1007/s11010-017-3157-z .
"Regulation of hepatic Na+/K+-ATPase in obese female and male rats: involvement of ERK1/2, AMPK, and Rho/ROCK" in Molecular and Cellular Biochemistry, 440 (2018):77-88,
https://doi.org/10.1007/s11010-017-3157-z . .
12
8
8

IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway

Panić, Anastasija; Stanimirović, Julijana; Obradović, Milan M.; Sudar-Milovanović, Emina; Isenović, Esma R.

(2018)

TY  - CONF
AU  - Panić, Anastasija
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0021915018307135
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7944
C3  - Atherosclerosis
T1  - IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway
VL  - 275
SP  - e137
DO  - 10.1016/j.atherosclerosis.2018.06.401
ER  - 
@conference{
author = "Panić, Anastasija and Stanimirović, Julijana and Obradović, Milan M. and Sudar-Milovanović, Emina and Isenović, Esma R.",
year = "2018",
journal = "Atherosclerosis",
title = "IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway",
volume = "275",
pages = "e137",
doi = "10.1016/j.atherosclerosis.2018.06.401"
}
Panić, A., Stanimirović, J., Obradović, M. M., Sudar-Milovanović, E.,& Isenović, E. R.. (2018). IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway. in Atherosclerosis, 275, e137.
https://doi.org/10.1016/j.atherosclerosis.2018.06.401
Panić A, Stanimirović J, Obradović MM, Sudar-Milovanović E, Isenović ER. IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway. in Atherosclerosis. 2018;275:e137.
doi:10.1016/j.atherosclerosis.2018.06.401 .
Panić, Anastasija, Stanimirović, Julijana, Obradović, Milan M., Sudar-Milovanović, Emina, Isenović, Esma R., "IGF-1 regulates cardiac hypertrophy and inos expression in obese male rats through ERK1/2 signaling pathway" in Atherosclerosis, 275 (2018):e137,
https://doi.org/10.1016/j.atherosclerosis.2018.06.401 . .

Influence of a High-fat Diet on Cardiac iNOS in Female Rats

Jovanović, Aleksandra; Sudar, Emina; Obradović, Milan M.; Pitt, Samantha J.; Stewart, Alan J.; Zafirović, Sonja; Stanimirović, Julijana; Radak, Đorđe J.; Isenović, Esma R.

(2017)

TY  - JOUR
AU  - Jovanović, Aleksandra
AU  - Sudar, Emina
AU  - Obradović, Milan M.
AU  - Pitt, Samantha J.
AU  - Stewart, Alan J.
AU  - Zafirović, Sonja
AU  - Stanimirović, Julijana
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1678
AB  - Background: Overexpression of inducible nitric oxide synthase (iNOS) is a key link between high-fat (HF) diet induced obesity and cardiovascular disease. Oestradiol has cardioprotective effects that may be mediated through reduction of iNOS activity/expression. Methods: In the present study, female Wistar rats were fed a standard diet or a HF diet (42% fat) for 10 weeks. iNOS gene and protein expressions were measured in heart tissue. HF-fed rats exhibited a significant increase in cardiac iNOS mRNA by 695% (p LT 0.05), iNOS protein level by 248% (p LT 0.01), without changes in nitrate/nitrite levels. Expression of CD36 protein in plasma membranes was increased by 37% (p LT 0.05), while the concentration of free fatty acids (FFA) was reduced by 25% (p LT 0.01) in HF-fed rats. Expression of the p50 subunit of nuclear factor-kappa B (NF kappa B-p50) in heart was increased by 77% (p LT 0.01) in HF-fed rats. Expression of protein kinase B (Akt) and extracellular signal-regulated kinases 1/2 (ERK1/2) were unchanged between the groups. There was a significant increase in the ratio of phospho-Akt/total Akt but not for phospho-ERK1/2/total ERK1/2 in HF-fed rats. Estrogen receptor-levels (by 50%; p LT 0.05) and serum oestradiol concentrations (by 35%; p LT 0.05) were shown to be significantly reduced in HF-fed rats. Results and Conclusion: Our results revealed that a HF diet led to increased iNOS expression, most likely via a mechanism involving Akt and NF kappa B-p50 proteins. Decreased levels of oestradiol and ER protein in the HF-fed group, in combination with increased iNOS levels are consistent with the hypothesis that oestradiol has a cardioprotective effect through its ability to regulate iNOS expression.
T2  - Current Vascular Pharmacology
T1  - Influence of a High-fat Diet on Cardiac iNOS in Female Rats
VL  - 15
IS  - 5
SP  - 491
EP  - 500
DO  - 10.2174/1570161114666161025101303
ER  - 
@article{
author = "Jovanović, Aleksandra and Sudar, Emina and Obradović, Milan M. and Pitt, Samantha J. and Stewart, Alan J. and Zafirović, Sonja and Stanimirović, Julijana and Radak, Đorđe J. and Isenović, Esma R.",
year = "2017",
abstract = "Background: Overexpression of inducible nitric oxide synthase (iNOS) is a key link between high-fat (HF) diet induced obesity and cardiovascular disease. Oestradiol has cardioprotective effects that may be mediated through reduction of iNOS activity/expression. Methods: In the present study, female Wistar rats were fed a standard diet or a HF diet (42% fat) for 10 weeks. iNOS gene and protein expressions were measured in heart tissue. HF-fed rats exhibited a significant increase in cardiac iNOS mRNA by 695% (p LT 0.05), iNOS protein level by 248% (p LT 0.01), without changes in nitrate/nitrite levels. Expression of CD36 protein in plasma membranes was increased by 37% (p LT 0.05), while the concentration of free fatty acids (FFA) was reduced by 25% (p LT 0.01) in HF-fed rats. Expression of the p50 subunit of nuclear factor-kappa B (NF kappa B-p50) in heart was increased by 77% (p LT 0.01) in HF-fed rats. Expression of protein kinase B (Akt) and extracellular signal-regulated kinases 1/2 (ERK1/2) were unchanged between the groups. There was a significant increase in the ratio of phospho-Akt/total Akt but not for phospho-ERK1/2/total ERK1/2 in HF-fed rats. Estrogen receptor-levels (by 50%; p LT 0.05) and serum oestradiol concentrations (by 35%; p LT 0.05) were shown to be significantly reduced in HF-fed rats. Results and Conclusion: Our results revealed that a HF diet led to increased iNOS expression, most likely via a mechanism involving Akt and NF kappa B-p50 proteins. Decreased levels of oestradiol and ER protein in the HF-fed group, in combination with increased iNOS levels are consistent with the hypothesis that oestradiol has a cardioprotective effect through its ability to regulate iNOS expression.",
journal = "Current Vascular Pharmacology",
title = "Influence of a High-fat Diet on Cardiac iNOS in Female Rats",
volume = "15",
number = "5",
pages = "491-500",
doi = "10.2174/1570161114666161025101303"
}
Jovanović, A., Sudar, E., Obradović, M. M., Pitt, S. J., Stewart, A. J., Zafirović, S., Stanimirović, J., Radak, Đ. J.,& Isenović, E. R.. (2017). Influence of a High-fat Diet on Cardiac iNOS in Female Rats. in Current Vascular Pharmacology, 15(5), 491-500.
https://doi.org/10.2174/1570161114666161025101303
Jovanović A, Sudar E, Obradović MM, Pitt SJ, Stewart AJ, Zafirović S, Stanimirović J, Radak ĐJ, Isenović ER. Influence of a High-fat Diet on Cardiac iNOS in Female Rats. in Current Vascular Pharmacology. 2017;15(5):491-500.
doi:10.2174/1570161114666161025101303 .
Jovanović, Aleksandra, Sudar, Emina, Obradović, Milan M., Pitt, Samantha J., Stewart, Alan J., Zafirović, Sonja, Stanimirović, Julijana, Radak, Đorđe J., Isenović, Esma R., "Influence of a High-fat Diet on Cardiac iNOS in Female Rats" in Current Vascular Pharmacology, 15, no. 5 (2017):491-500,
https://doi.org/10.2174/1570161114666161025101303 . .
17
9
16

17 beta-Estradiol protects against the effects of a high fat diet on cardiac glucose, lipid and nitric oxide metabolism in rats

Zafirović, Sonja; Obradović, Milan M.; Sudar-Milovanović, Emina; Jovanović, Aleksandra; Stanimirović, Julijana; Stewart, Alan J.; Pitt, Samantha J.; Isenović, Esma R.

(2017)

TY  - JOUR
AU  - Zafirović, Sonja
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Jovanović, Aleksandra
AU  - Stanimirović, Julijana
AU  - Stewart, Alan J.
AU  - Pitt, Samantha J.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1520
AB  - The aim of this study was to investigate the in vivo effects of 17 beta-estradiol (E-2) on myocardial metabolism and inducible nitric oxide synthase (iNOS) expression/activity in obese rats. Male Wistar rats were fed with a normal or a high fat (HF) diet (42% fat) for 10 weeks. Half of the HF fed rats were treated with a single dose of E-2 while the other half were placebo-treated. 24 h after treatment animals were sacrificed. E-2 reduced cardiac free fatty acid (FFA) (p LT 0.05), L-arginine (p LT 0.01), iNOS mRNA (p LT 0.01), and protein (p LT 0.05) levels and translocation of the FFA transporter (CD36) (p LT 0.01) to the plasma membrane (PM) in HF fed rats. In contrast, Akt phosphorylation at Thr308 (p LT 0.05) and translocation of the glucose transporter GLUT4 (p LT 0.05) to the PM increased after E-2 treatment in HF rats. Our results indicate that E-2 acts via the PI3K/Akt signalling pathway to partially protect myocardial metabolism by attenuating the detrimental effects of increased iNOS expression/activity in HF fed rats. (C) 2017 Elsevier B.V. All rights reserved.
T2  - Molecular and Cellular Endocrinology
T1  - 17 beta-Estradiol protects against the effects of a high fat diet on cardiac glucose, lipid and nitric oxide metabolism in rats
VL  - 446
IS  - C
SP  - 12
EP  - 20
DO  - 10.1016/j.mce.2017.02.001
ER  - 
@article{
author = "Zafirović, Sonja and Obradović, Milan M. and Sudar-Milovanović, Emina and Jovanović, Aleksandra and Stanimirović, Julijana and Stewart, Alan J. and Pitt, Samantha J. and Isenović, Esma R.",
year = "2017",
abstract = "The aim of this study was to investigate the in vivo effects of 17 beta-estradiol (E-2) on myocardial metabolism and inducible nitric oxide synthase (iNOS) expression/activity in obese rats. Male Wistar rats were fed with a normal or a high fat (HF) diet (42% fat) for 10 weeks. Half of the HF fed rats were treated with a single dose of E-2 while the other half were placebo-treated. 24 h after treatment animals were sacrificed. E-2 reduced cardiac free fatty acid (FFA) (p LT 0.05), L-arginine (p LT 0.01), iNOS mRNA (p LT 0.01), and protein (p LT 0.05) levels and translocation of the FFA transporter (CD36) (p LT 0.01) to the plasma membrane (PM) in HF fed rats. In contrast, Akt phosphorylation at Thr308 (p LT 0.05) and translocation of the glucose transporter GLUT4 (p LT 0.05) to the PM increased after E-2 treatment in HF rats. Our results indicate that E-2 acts via the PI3K/Akt signalling pathway to partially protect myocardial metabolism by attenuating the detrimental effects of increased iNOS expression/activity in HF fed rats. (C) 2017 Elsevier B.V. All rights reserved.",
journal = "Molecular and Cellular Endocrinology",
title = "17 beta-Estradiol protects against the effects of a high fat diet on cardiac glucose, lipid and nitric oxide metabolism in rats",
volume = "446",
number = "C",
pages = "12-20",
doi = "10.1016/j.mce.2017.02.001"
}
Zafirović, S., Obradović, M. M., Sudar-Milovanović, E., Jovanović, A., Stanimirović, J., Stewart, A. J., Pitt, S. J.,& Isenović, E. R.. (2017). 17 beta-Estradiol protects against the effects of a high fat diet on cardiac glucose, lipid and nitric oxide metabolism in rats. in Molecular and Cellular Endocrinology, 446(C), 12-20.
https://doi.org/10.1016/j.mce.2017.02.001
Zafirović S, Obradović MM, Sudar-Milovanović E, Jovanović A, Stanimirović J, Stewart AJ, Pitt SJ, Isenović ER. 17 beta-Estradiol protects against the effects of a high fat diet on cardiac glucose, lipid and nitric oxide metabolism in rats. in Molecular and Cellular Endocrinology. 2017;446(C):12-20.
doi:10.1016/j.mce.2017.02.001 .
Zafirović, Sonja, Obradović, Milan M., Sudar-Milovanović, Emina, Jovanović, Aleksandra, Stanimirović, Julijana, Stewart, Alan J., Pitt, Samantha J., Isenović, Esma R., "17 beta-Estradiol protects against the effects of a high fat diet on cardiac glucose, lipid and nitric oxide metabolism in rats" in Molecular and Cellular Endocrinology, 446, no. C (2017):12-20,
https://doi.org/10.1016/j.mce.2017.02.001 . .
12
7
12

Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases

Obradović, Milan M.; Stanimirović, Julijana; Panić, Anastasija; Bogdanović, Nikola; Sudar, Emina; Cenić-Milošević, Desanka; Isenović, Esma R.

(2017)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Stanimirović, Julijana
AU  - Panić, Anastasija
AU  - Bogdanović, Nikola
AU  - Sudar, Emina
AU  - Cenić-Milošević, Desanka
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1581
AB  - Background: The sodium/potassium- adenosine- triphosphatase (Na+/K+-ATPase) is an important mediator in vasculature tone and contractility, and its abnormal regulation has been implicated in many diseases such as obesity, insulin resistance, diabetes, and hypertension. Decreased Na+/K+-ATPase abundance and its altered isoform expression induce cardiomyocytes death and cardiac dysfunction, possibly leading to the development of myocardial dilation and heart failure. Therefore, the regulation of Na+/K+-ATPase activity/expression could be important in treatment and possible prevention of cardio-metabolic diseases. A number of hormones and environmental factors regulate the function of Na+/K+-ATPase in response to changing cellular requirements. Estradiol and insulin like growth factor-1 (IGF-1) are among potent hormones that positively regulate Na+/K+-ATPase activity or de novo synthesis of alpha -and beta -subunits. Both estradiol and IGF-1 have a huge therapeutic potential in treatment of vasculopathy in cardio-metabolic diseases. Methods: We searched the MEDLINE and PUBMED databases for all English and non-English articles with an English abstract from April 1978 to May 2016. The main data search terms were: Na+/K+-ATPase; estradiol and Na+/K+-ATPase; estradiol, Na+/K+-ATPase and CVS; estradiol, Na+/K+-ATPase and CVD; estradiol, Na+/K+-ATPase and obesity; estradiol, Na+/K+-ATPase and diabetes; estradiol, Na+/K+-ATPase and hypertension; IGF-1; IGF-1 and Na+/K+-ATPase; IGF-1, Na+/K+-ATPase and CVS; IGF-1, Na+/K+-ATPase and CVD; IGF-1, Na+/K+-ATPase and obesity; IGF-1, Na+/K+-ATPase and diabetes; IGF-1, Na+/K+-ATPase and hypertension. Results: The present review discusses the latest data from animal and human studies which focus on the effects of estradiol and IGF-1 on Na+/K+-ATPase regulation in physiological and pathophysiological conditions in cardiovascular system. Conclusion: Understanding the molecular mechanisms of estradiol and IGF-1 action on Na+/K+-ATPase in humans, may help resolving outstanding issues and developing new strategies for the protection and treatment of cardiovascular diseases.
T2  - Current Pharmaceutical Design
T1  - Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases
VL  - 23
IS  - 10
SP  - 1551
EP  - 1561
DO  - 10.2174/1381612823666170203113455
ER  - 
@article{
author = "Obradović, Milan M. and Stanimirović, Julijana and Panić, Anastasija and Bogdanović, Nikola and Sudar, Emina and Cenić-Milošević, Desanka and Isenović, Esma R.",
year = "2017",
abstract = "Background: The sodium/potassium- adenosine- triphosphatase (Na+/K+-ATPase) is an important mediator in vasculature tone and contractility, and its abnormal regulation has been implicated in many diseases such as obesity, insulin resistance, diabetes, and hypertension. Decreased Na+/K+-ATPase abundance and its altered isoform expression induce cardiomyocytes death and cardiac dysfunction, possibly leading to the development of myocardial dilation and heart failure. Therefore, the regulation of Na+/K+-ATPase activity/expression could be important in treatment and possible prevention of cardio-metabolic diseases. A number of hormones and environmental factors regulate the function of Na+/K+-ATPase in response to changing cellular requirements. Estradiol and insulin like growth factor-1 (IGF-1) are among potent hormones that positively regulate Na+/K+-ATPase activity or de novo synthesis of alpha -and beta -subunits. Both estradiol and IGF-1 have a huge therapeutic potential in treatment of vasculopathy in cardio-metabolic diseases. Methods: We searched the MEDLINE and PUBMED databases for all English and non-English articles with an English abstract from April 1978 to May 2016. The main data search terms were: Na+/K+-ATPase; estradiol and Na+/K+-ATPase; estradiol, Na+/K+-ATPase and CVS; estradiol, Na+/K+-ATPase and CVD; estradiol, Na+/K+-ATPase and obesity; estradiol, Na+/K+-ATPase and diabetes; estradiol, Na+/K+-ATPase and hypertension; IGF-1; IGF-1 and Na+/K+-ATPase; IGF-1, Na+/K+-ATPase and CVS; IGF-1, Na+/K+-ATPase and CVD; IGF-1, Na+/K+-ATPase and obesity; IGF-1, Na+/K+-ATPase and diabetes; IGF-1, Na+/K+-ATPase and hypertension. Results: The present review discusses the latest data from animal and human studies which focus on the effects of estradiol and IGF-1 on Na+/K+-ATPase regulation in physiological and pathophysiological conditions in cardiovascular system. Conclusion: Understanding the molecular mechanisms of estradiol and IGF-1 action on Na+/K+-ATPase in humans, may help resolving outstanding issues and developing new strategies for the protection and treatment of cardiovascular diseases.",
journal = "Current Pharmaceutical Design",
title = "Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases",
volume = "23",
number = "10",
pages = "1551-1561",
doi = "10.2174/1381612823666170203113455"
}
Obradović, M. M., Stanimirović, J., Panić, A., Bogdanović, N., Sudar, E., Cenić-Milošević, D.,& Isenović, E. R.. (2017). Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases. in Current Pharmaceutical Design, 23(10), 1551-1561.
https://doi.org/10.2174/1381612823666170203113455
Obradović MM, Stanimirović J, Panić A, Bogdanović N, Sudar E, Cenić-Milošević D, Isenović ER. Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases. in Current Pharmaceutical Design. 2017;23(10):1551-1561.
doi:10.2174/1381612823666170203113455 .
Obradović, Milan M., Stanimirović, Julijana, Panić, Anastasija, Bogdanović, Nikola, Sudar, Emina, Cenić-Milošević, Desanka, Isenović, Esma R., "Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases" in Current Pharmaceutical Design, 23, no. 10 (2017):1551-1561,
https://doi.org/10.2174/1381612823666170203113455 . .
14
7
15

A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats

Stanimirović, Julijana; Obradović, Milan M.; Jovanović, Aleksandra; Sudar, Emina; Zafirović, Sonja; Pitt, Samantha J.; Stewart, Alan J.; Isenović, Esma R.

(Elsevier, 2016)

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Jovanović, Aleksandra
AU  - Sudar, Emina
AU  - Zafirović, Sonja
AU  - Pitt, Samantha J.
AU  - Stewart, Alan J.
AU  - Isenović, Esma R.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1004
AB  - Men and women differ substantially with regard to the severity of insulin resistance (IR) but the underlying mechanism(s) of how this occurs is poorly characterized. We investigated whether a high fat (HF) diet resulted in sex-specific differences in nitrite/nitrate production and lipid metabolism and whether these variances may contribute to altered obesity-induced IR. Male and female Wistar rats were fed a standard laboratory diet or a HF diet for 10 weeks. The level of plasma nitrite/nitrate, as well as free fatty acid (FFA), in both plasma and liver lysates were assessed. The levels of inducible nitric oxide (NO) synthase (iNOS), p65 subunit of NF kappa B, total and phosphorylated forms of Akt, mTOR and PDK-1 in lysates, and the levels of glucose transporter 2 (Glut-2) and fatty acid translocase/cluster of differentiation 36 (FAT/CD36) in plasma membrane fractions of liver were assessed. HF-fed male rats exhibited a significant increase in plasma nitrite/nitrate, and hepatic FFA and FAT/CD36 levels compared with controls. They also displayed a relative decrease in iNOS and Glut-2 levels in the liver. Phosphorylation of Akt (at Ser(473) and Thr(308)), mTOR and PDK-1 was also reduced. HF-fed female rats exhibited increased levels of NF kappa B-p65 in liver compared with controls, while levels of Glut-2, FAT/CD36 and Akt phosphorylation at Thr(308) and PDK-1 were decreased. Our results reveal that altered lipid and glucose metabolism in obesity, lead to altered iNOS expression and nitrite/nitrate production. It is likely that this mechanism contributes to sex-specific differences in the development of IR. (C) 2016 Elsevier Inc. All rights reserved.
PB  - Elsevier
T2  - Nitric Oxide: Biology and Chemistry
T1  - A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats
VL  - 54
SP  - 51
EP  - 59
DO  - 10.1016/j.niox.2016.02.007
ER  - 
@article{
author = "Stanimirović, Julijana and Obradović, Milan M. and Jovanović, Aleksandra and Sudar, Emina and Zafirović, Sonja and Pitt, Samantha J. and Stewart, Alan J. and Isenović, Esma R.",
year = "2016",
abstract = "Men and women differ substantially with regard to the severity of insulin resistance (IR) but the underlying mechanism(s) of how this occurs is poorly characterized. We investigated whether a high fat (HF) diet resulted in sex-specific differences in nitrite/nitrate production and lipid metabolism and whether these variances may contribute to altered obesity-induced IR. Male and female Wistar rats were fed a standard laboratory diet or a HF diet for 10 weeks. The level of plasma nitrite/nitrate, as well as free fatty acid (FFA), in both plasma and liver lysates were assessed. The levels of inducible nitric oxide (NO) synthase (iNOS), p65 subunit of NF kappa B, total and phosphorylated forms of Akt, mTOR and PDK-1 in lysates, and the levels of glucose transporter 2 (Glut-2) and fatty acid translocase/cluster of differentiation 36 (FAT/CD36) in plasma membrane fractions of liver were assessed. HF-fed male rats exhibited a significant increase in plasma nitrite/nitrate, and hepatic FFA and FAT/CD36 levels compared with controls. They also displayed a relative decrease in iNOS and Glut-2 levels in the liver. Phosphorylation of Akt (at Ser(473) and Thr(308)), mTOR and PDK-1 was also reduced. HF-fed female rats exhibited increased levels of NF kappa B-p65 in liver compared with controls, while levels of Glut-2, FAT/CD36 and Akt phosphorylation at Thr(308) and PDK-1 were decreased. Our results reveal that altered lipid and glucose metabolism in obesity, lead to altered iNOS expression and nitrite/nitrate production. It is likely that this mechanism contributes to sex-specific differences in the development of IR. (C) 2016 Elsevier Inc. All rights reserved.",
publisher = "Elsevier",
journal = "Nitric Oxide: Biology and Chemistry",
title = "A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats",
volume = "54",
pages = "51-59",
doi = "10.1016/j.niox.2016.02.007"
}
Stanimirović, J., Obradović, M. M., Jovanović, A., Sudar, E., Zafirović, S., Pitt, S. J., Stewart, A. J.,& Isenović, E. R.. (2016). A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats. in Nitric Oxide: Biology and Chemistry
Elsevier., 54, 51-59.
https://doi.org/10.1016/j.niox.2016.02.007
Stanimirović J, Obradović MM, Jovanović A, Sudar E, Zafirović S, Pitt SJ, Stewart AJ, Isenović ER. A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats. in Nitric Oxide: Biology and Chemistry. 2016;54:51-59.
doi:10.1016/j.niox.2016.02.007 .
Stanimirović, Julijana, Obradović, Milan M., Jovanović, Aleksandra, Sudar, Emina, Zafirović, Sonja, Pitt, Samantha J., Stewart, Alan J., Isenović, Esma R., "A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats" in Nitric Oxide: Biology and Chemistry, 54 (2016):51-59,
https://doi.org/10.1016/j.niox.2016.02.007 . .
3
25
24
29

Treatment of Alzheimers Disease: Classical Therapeutic Approach

Bajić, Vladan P.; Sudar, Emina; Spremo-Potparević, Biljana; Živković, Lada; Milićević, Zorka T.; Stanimirović, Julijana; Bogdanović, Nikola; Isenović, Esma R.

(Bentham Science Publishers, 2016)

TY  - JOUR
AU  - Bajić, Vladan P.
AU  - Sudar, Emina
AU  - Spremo-Potparević, Biljana
AU  - Živković, Lada
AU  - Milićević, Zorka T.
AU  - Stanimirović, Julijana
AU  - Bogdanović, Nikola
AU  - Isenović, Esma R.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1039
AB  - Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
PB  - Bentham Science Publishers
T2  - Current Pharmaceutical Analysis
T1  - Treatment of Alzheimers Disease: Classical Therapeutic Approach
VL  - 12
IS  - 2
SP  - 82
EP  - 90
DO  - 10.2174/1573412911666150611184740
ER  - 
@article{
author = "Bajić, Vladan P. and Sudar, Emina and Spremo-Potparević, Biljana and Živković, Lada and Milićević, Zorka T. and Stanimirović, Julijana and Bogdanović, Nikola and Isenović, Esma R.",
year = "2016",
abstract = "Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.",
publisher = "Bentham Science Publishers",
journal = "Current Pharmaceutical Analysis",
title = "Treatment of Alzheimers Disease: Classical Therapeutic Approach",
volume = "12",
number = "2",
pages = "82-90",
doi = "10.2174/1573412911666150611184740"
}
Bajić, V. P., Sudar, E., Spremo-Potparević, B., Živković, L., Milićević, Z. T., Stanimirović, J., Bogdanović, N.,& Isenović, E. R.. (2016). Treatment of Alzheimers Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis
Bentham Science Publishers., 12(2), 82-90.
https://doi.org/10.2174/1573412911666150611184740
Bajić VP, Sudar E, Spremo-Potparević B, Živković L, Milićević ZT, Stanimirović J, Bogdanović N, Isenović ER. Treatment of Alzheimers Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis. 2016;12(2):82-90.
doi:10.2174/1573412911666150611184740 .
Bajić, Vladan P., Sudar, Emina, Spremo-Potparević, Biljana, Živković, Lada, Milićević, Zorka T., Stanimirović, Julijana, Bogdanović, Nikola, Isenović, Esma R., "Treatment of Alzheimers Disease: Classical Therapeutic Approach" in Current Pharmaceutical Analysis, 12, no. 2 (2016):82-90,
https://doi.org/10.2174/1573412911666150611184740 . .
15
12
13

Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS

Stanimirović, Julijana; Obradović, Milan M.; Zafirović, Sonja; Resanović, Ivana; Bogdanović, Nikola; Gluvić, Zoran; Mousa, Shaker A.; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Resanović, Ivana
AU  - Bogdanović, Nikola
AU  - Gluvić, Zoran
AU  - Mousa, Shaker A.
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/511
AB  - An altered hepatic lipid metabolism involves multifactorial pathologies such as hepatic inflammation, insulin resistance and oxidative stress. Immunity has an essential role in the regulation of glucose and lipid metabolism in the liver. Inducible nitric oxide (NO) synthase (iNOS) has been proposed as an important factor that interplays between immunity and energy metabolism and also in the pathogenesis of obesity-linked insulin resistance. In the liver, locally produced NO plays a protective role during inflammation, and the balance of NO protective and cytotoxic effects is very important. This review is focused on understanding the molecular mechanisms of iNOS regulation in the state of altered hepatic lipid metabolism, which is critical for developing new strategies for treatment of hepatic disorders.
T2  - Clinical Lipidology
T1  - Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS
VL  - 10
IS  - 2
SP  - 167
EP  - 175
DO  - 10.2217/CLP.15.8
ER  - 
@article{
author = "Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Resanović, Ivana and Bogdanović, Nikola and Gluvić, Zoran and Mousa, Shaker A. and Isenović, Esma R.",
year = "2015",
abstract = "An altered hepatic lipid metabolism involves multifactorial pathologies such as hepatic inflammation, insulin resistance and oxidative stress. Immunity has an essential role in the regulation of glucose and lipid metabolism in the liver. Inducible nitric oxide (NO) synthase (iNOS) has been proposed as an important factor that interplays between immunity and energy metabolism and also in the pathogenesis of obesity-linked insulin resistance. In the liver, locally produced NO plays a protective role during inflammation, and the balance of NO protective and cytotoxic effects is very important. This review is focused on understanding the molecular mechanisms of iNOS regulation in the state of altered hepatic lipid metabolism, which is critical for developing new strategies for treatment of hepatic disorders.",
journal = "Clinical Lipidology",
title = "Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS",
volume = "10",
number = "2",
pages = "167-175",
doi = "10.2217/CLP.15.8"
}
Stanimirović, J., Obradović, M. M., Zafirović, S., Resanović, I., Bogdanović, N., Gluvić, Z., Mousa, S. A.,& Isenović, E. R.. (2015). Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. in Clinical Lipidology, 10(2), 167-175.
https://doi.org/10.2217/CLP.15.8
Stanimirović J, Obradović MM, Zafirović S, Resanović I, Bogdanović N, Gluvić Z, Mousa SA, Isenović ER. Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. in Clinical Lipidology. 2015;10(2):167-175.
doi:10.2217/CLP.15.8 .
Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Resanović, Ivana, Bogdanović, Nikola, Gluvić, Zoran, Mousa, Shaker A., Isenović, Esma R., "Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS" in Clinical Lipidology, 10, no. 2 (2015):167-175,
https://doi.org/10.2217/CLP.15.8 . .
9
10

Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases

Trpković, Andreja; Resanović, Ivana; Stanimirović, Julijana; Radak, Đorđe J.; Mousa, Shaker A.; Cenić-Milošević, Desanka; Jevremovic, Danimir; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Trpković, Andreja
AU  - Resanović, Ivana
AU  - Stanimirović, Julijana
AU  - Radak, Đorđe J.
AU  - Mousa, Shaker A.
AU  - Cenić-Milošević, Desanka
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/635
AB  - Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.
T2  - Critical Reviews in Clinical Laboratory Sciences
T1  - Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
VL  - 52
IS  - 2
SP  - 70
EP  - 85
DO  - 10.3109/10408363.2014.992063
ER  - 
@article{
author = "Trpković, Andreja and Resanović, Ivana and Stanimirović, Julijana and Radak, Đorđe J. and Mousa, Shaker A. and Cenić-Milošević, Desanka and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.",
journal = "Critical Reviews in Clinical Laboratory Sciences",
title = "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases",
volume = "52",
number = "2",
pages = "70-85",
doi = "10.3109/10408363.2014.992063"
}
Trpković, A., Resanović, I., Stanimirović, J., Radak, Đ. J., Mousa, S. A., Cenić-Milošević, D., Jevremovic, D.,& Isenović, E. R.. (2015). Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences, 52(2), 70-85.
https://doi.org/10.3109/10408363.2014.992063
Trpković A, Resanović I, Stanimirović J, Radak ĐJ, Mousa SA, Cenić-Milošević D, Jevremovic D, Isenović ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences. 2015;52(2):70-85.
doi:10.3109/10408363.2014.992063 .
Trpković, Andreja, Resanović, Ivana, Stanimirović, Julijana, Radak, Đorđe J., Mousa, Shaker A., Cenić-Milošević, Desanka, Jevremovic, Danimir, Isenović, Esma R., "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases" in Critical Reviews in Clinical Laboratory Sciences, 52, no. 2 (2015):70-85,
https://doi.org/10.3109/10408363.2014.992063 . .
22
246
174

Lečenje sindroma plavih prstiju hiperbaričnom oksigenoterapijom - prikaz slučaja

Milačić-Davorka, M.; Matković, Tatjana; Lalić, Anja; Stanimirović, Julijana; Gluvić, Zoran; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Milačić-Davorka, M.
AU  - Matković, Tatjana
AU  - Lalić, Anja
AU  - Stanimirović, Julijana
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10314
AB  - Sindrom plavih prstiju je relativno redak ishemijski poremećaj, nastao usled okluzije malih krvnih sudova fragmentima aterosklerotičnih plakova sačinjenih od kristala holesterola, masnih kiselina i kalcijuma. Može se pojaviti kao komplikacija nakon endovaskularne procedure, najčešće na infrarenalnom delu abdominalne aorte, ali i kod bolesnika koji su na oralnoj antikoagulantnoj terapiji (OAKT). Hiperbarična oksigenoterapija (HBOt) predstavlja udisanje 100% kiseonika u pažljivo kontrolisanim uslovima povišenog pritiska. Prikazan je slučaj primene HBOt u tretmanu bolesnice sa sindromom plavih prstiju, koji se javio nakon endovaskularne procedure na infrarenalnoj aneurizmi abdominalne aorte (AAA). Po završenoj HBOt, došlo je do potpune regresije ishemijskih promena.
AB  - "Blue toe" syndrome is a relatively rare ischemic disorder produced by occlusion of small blood vessels with fragments of atherosclerotic plaques composed of cholesterol crystals, fatty acids and calcium. It can occur as a complication after endovascular procedures, usually performed on the infra-renal segment of abdominal aorta, as well as in the patients who were under treatment with oral anticoagulant therapy. Hyperbaric oxygen therapy (HBOt) is inhaling 100% oxygen under carefully controlled elevated pressure conditions. In Zemun Clinical Hospital, a patient who presented with "blue toe" syndrome, has been treated with HBOt. After the completion of HBOt course, there was an almost complete regression of ischemic changes.
T2  - Medicinska istraživanja
T1  - Lečenje sindroma plavih prstiju hiperbaričnom oksigenoterapijom - prikaz slučaja
T1  - Treatment of "Blue toe" syndrome with Hyperbaric oxygen therapy: Case study
VL  - 49
IS  - 2
SP  - 46
EP  - 49
DO  - 10.5937/MedIst1502046M
ER  - 
@article{
author = "Milačić-Davorka, M. and Matković, Tatjana and Lalić, Anja and Stanimirović, Julijana and Gluvić, Zoran and Isenović, Esma R.",
year = "2015",
abstract = "Sindrom plavih prstiju je relativno redak ishemijski poremećaj, nastao usled okluzije malih krvnih sudova fragmentima aterosklerotičnih plakova sačinjenih od kristala holesterola, masnih kiselina i kalcijuma. Može se pojaviti kao komplikacija nakon endovaskularne procedure, najčešće na infrarenalnom delu abdominalne aorte, ali i kod bolesnika koji su na oralnoj antikoagulantnoj terapiji (OAKT). Hiperbarična oksigenoterapija (HBOt) predstavlja udisanje 100% kiseonika u pažljivo kontrolisanim uslovima povišenog pritiska. Prikazan je slučaj primene HBOt u tretmanu bolesnice sa sindromom plavih prstiju, koji se javio nakon endovaskularne procedure na infrarenalnoj aneurizmi abdominalne aorte (AAA). Po završenoj HBOt, došlo je do potpune regresije ishemijskih promena., "Blue toe" syndrome is a relatively rare ischemic disorder produced by occlusion of small blood vessels with fragments of atherosclerotic plaques composed of cholesterol crystals, fatty acids and calcium. It can occur as a complication after endovascular procedures, usually performed on the infra-renal segment of abdominal aorta, as well as in the patients who were under treatment with oral anticoagulant therapy. Hyperbaric oxygen therapy (HBOt) is inhaling 100% oxygen under carefully controlled elevated pressure conditions. In Zemun Clinical Hospital, a patient who presented with "blue toe" syndrome, has been treated with HBOt. After the completion of HBOt course, there was an almost complete regression of ischemic changes.",
journal = "Medicinska istraživanja",
title = "Lečenje sindroma plavih prstiju hiperbaričnom oksigenoterapijom - prikaz slučaja, Treatment of "Blue toe" syndrome with Hyperbaric oxygen therapy: Case study",
volume = "49",
number = "2",
pages = "46-49",
doi = "10.5937/MedIst1502046M"
}
Milačić-Davorka, M., Matković, T., Lalić, A., Stanimirović, J., Gluvić, Z.,& Isenović, E. R.. (2015). Lečenje sindroma plavih prstiju hiperbaričnom oksigenoterapijom - prikaz slučaja. in Medicinska istraživanja, 49(2), 46-49.
https://doi.org/10.5937/MedIst1502046M
Milačić-Davorka M, Matković T, Lalić A, Stanimirović J, Gluvić Z, Isenović ER. Lečenje sindroma plavih prstiju hiperbaričnom oksigenoterapijom - prikaz slučaja. in Medicinska istraživanja. 2015;49(2):46-49.
doi:10.5937/MedIst1502046M .
Milačić-Davorka, M., Matković, Tatjana, Lalić, Anja, Stanimirović, Julijana, Gluvić, Zoran, Isenović, Esma R., "Lečenje sindroma plavih prstiju hiperbaričnom oksigenoterapijom - prikaz slučaja" in Medicinska istraživanja, 49, no. 2 (2015):46-49,
https://doi.org/10.5937/MedIst1502046M . .

High-Sensitivity C-Reactive Protein and Statin Initiation

Trpković, Andreja; Stanimirović, Julijana; Rizzo, Manfredi; Resanović, Ivana; Soskić, Sanja S.; Jevremovic, Danimir; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Rizzo, Manfredi
AU  - Resanović, Ivana
AU  - Soskić, Sanja S.
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/613
AB  - The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.
T2  - Angiology
T1  - High-Sensitivity C-Reactive Protein and Statin Initiation
VL  - 66
IS  - 6
SP  - 503
EP  - 507
DO  - 10.1177/0003319714543000
ER  - 
@article{
author = "Trpković, Andreja and Stanimirović, Julijana and Rizzo, Manfredi and Resanović, Ivana and Soskić, Sanja S. and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.",
journal = "Angiology",
title = "High-Sensitivity C-Reactive Protein and Statin Initiation",
volume = "66",
number = "6",
pages = "503-507",
doi = "10.1177/0003319714543000"
}
Trpković, A., Stanimirović, J., Rizzo, M., Resanović, I., Soskić, S. S., Jevremovic, D.,& Isenović, E. R.. (2015). High-Sensitivity C-Reactive Protein and Statin Initiation. in Angiology, 66(6), 503-507.
https://doi.org/10.1177/0003319714543000
Trpković A, Stanimirović J, Rizzo M, Resanović I, Soskić SS, Jevremovic D, Isenović ER. High-Sensitivity C-Reactive Protein and Statin Initiation. in Angiology. 2015;66(6):503-507.
doi:10.1177/0003319714543000 .
Trpković, Andreja, Stanimirović, Julijana, Rizzo, Manfredi, Resanović, Ivana, Soskić, Sanja S., Jevremovic, Danimir, Isenović, Esma R., "High-Sensitivity C-Reactive Protein and Statin Initiation" in Angiology, 66, no. 6 (2015):503-507,
https://doi.org/10.1177/0003319714543000 . .
1
1
2

Estradiol In Vivo Induces Changes in Cardiomyocytes Size in Obese Rats

Obradović, Milan M.; Sudar, Emina; Zafirović, Sonja; Stanimirović, Julijana; Labudović-Borović, Milica; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Sudar, Emina
AU  - Zafirović, Sonja
AU  - Stanimirović, Julijana
AU  - Labudović-Borović, Milica
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/286
AB  - We studied the in vivo effects of estradiol on size and biochemical parameters of cardiomyocytes in pathophysiological conditions such as obesity and insulin resistance. Male Wistar rats were normally fed (controls, n = 7) or fed with high-fat diet (obese, n = 14). Half of the obese rats (obese + estradiol, n = 7) were treated with a single dose of estradiol (40 g/kg, intraperitoneally) and 24 hours after treatment all the rats were killed. Estradiol in vivo in obese rats resulted in a significant increase in protein kinase B (Akt) activation (P LT .05) and decrease in heart mass (P LT .05), ratio of the heart mass/body mass (P LT .05), transverse diameters of cardiomyocytes (P LT .001), concentration of serum high-sensitivity C-reactive protein (P LT .001), and total cholesterol (P LT .01) compared with obese nontreated rats. Our results suggest that estradiol in obese/IR rats affects the size of cardiomyocytes and its actions lead in vivo to a reduction in obesity-induced cardiac hypertrophy, via Akt.
T2  - Angiology
T1  - Estradiol In Vivo Induces Changes in Cardiomyocytes Size in Obese Rats
VL  - 66
IS  - 1
SP  - 25
EP  - 35
DO  - 10.1177/0003319713514477
ER  - 
@article{
author = "Obradović, Milan M. and Sudar, Emina and Zafirović, Sonja and Stanimirović, Julijana and Labudović-Borović, Milica and Isenović, Esma R.",
year = "2015",
abstract = "We studied the in vivo effects of estradiol on size and biochemical parameters of cardiomyocytes in pathophysiological conditions such as obesity and insulin resistance. Male Wistar rats were normally fed (controls, n = 7) or fed with high-fat diet (obese, n = 14). Half of the obese rats (obese + estradiol, n = 7) were treated with a single dose of estradiol (40 g/kg, intraperitoneally) and 24 hours after treatment all the rats were killed. Estradiol in vivo in obese rats resulted in a significant increase in protein kinase B (Akt) activation (P LT .05) and decrease in heart mass (P LT .05), ratio of the heart mass/body mass (P LT .05), transverse diameters of cardiomyocytes (P LT .001), concentration of serum high-sensitivity C-reactive protein (P LT .001), and total cholesterol (P LT .01) compared with obese nontreated rats. Our results suggest that estradiol in obese/IR rats affects the size of cardiomyocytes and its actions lead in vivo to a reduction in obesity-induced cardiac hypertrophy, via Akt.",
journal = "Angiology",
title = "Estradiol In Vivo Induces Changes in Cardiomyocytes Size in Obese Rats",
volume = "66",
number = "1",
pages = "25-35",
doi = "10.1177/0003319713514477"
}
Obradović, M. M., Sudar, E., Zafirović, S., Stanimirović, J., Labudović-Borović, M.,& Isenović, E. R.. (2015). Estradiol In Vivo Induces Changes in Cardiomyocytes Size in Obese Rats. in Angiology, 66(1), 25-35.
https://doi.org/10.1177/0003319713514477
Obradović MM, Sudar E, Zafirović S, Stanimirović J, Labudović-Borović M, Isenović ER. Estradiol In Vivo Induces Changes in Cardiomyocytes Size in Obese Rats. in Angiology. 2015;66(1):25-35.
doi:10.1177/0003319713514477 .
Obradović, Milan M., Sudar, Emina, Zafirović, Sonja, Stanimirović, Julijana, Labudović-Borović, Milica, Isenović, Esma R., "Estradiol In Vivo Induces Changes in Cardiomyocytes Size in Obese Rats" in Angiology, 66, no. 1 (2015):25-35,
https://doi.org/10.1177/0003319713514477 . .
26
19
29

Interrelatedness between C-reactive protein and oxidized low-density lipoprotein

Obradović, Milan M.; Trpković, Andreja; Bajić, Vladan P.; Soskić, Sanja S.; Jovanović, Aleksandra; Stanimirović, Julijana; Panic, Milos; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Trpković, Andreja
AU  - Bajić, Vladan P.
AU  - Soskić, Sanja S.
AU  - Jovanović, Aleksandra
AU  - Stanimirović, Julijana
AU  - Panic, Milos
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/281
AB  - C-reactive protein (CRP) is a marker of inflammation. Atherosclerosis is now recognized as inflammatory disease, and it seems that CRP directly contributes to atherogenesis. Oxidation of low-density lipoprotein (LDL) molecule increases the uptake of lipid products by macrophages leading to cholesterol accumulation and subsequent foam cell formation. The elevated levels of high sensitivity CRP (hsCRP) and oxidized LDL (OxLDL) in the blood were found to be associated with cardiovascular diseases (CVD). In this review, we highlighted the evidence that CRP and OxLDL are involved in interrelated (patho) physiological pathways. The findings on association between hsCRP and OxLDL in the clinical setting will be also summarized.
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Interrelatedness between C-reactive protein and oxidized low-density lipoprotein
VL  - 53
IS  - 1
SP  - 29
EP  - 34
DO  - 10.1515/cclm-2014-0590
ER  - 
@article{
author = "Obradović, Milan M. and Trpković, Andreja and Bajić, Vladan P. and Soskić, Sanja S. and Jovanović, Aleksandra and Stanimirović, Julijana and Panic, Milos and Isenović, Esma R.",
year = "2015",
abstract = "C-reactive protein (CRP) is a marker of inflammation. Atherosclerosis is now recognized as inflammatory disease, and it seems that CRP directly contributes to atherogenesis. Oxidation of low-density lipoprotein (LDL) molecule increases the uptake of lipid products by macrophages leading to cholesterol accumulation and subsequent foam cell formation. The elevated levels of high sensitivity CRP (hsCRP) and oxidized LDL (OxLDL) in the blood were found to be associated with cardiovascular diseases (CVD). In this review, we highlighted the evidence that CRP and OxLDL are involved in interrelated (patho) physiological pathways. The findings on association between hsCRP and OxLDL in the clinical setting will be also summarized.",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Interrelatedness between C-reactive protein and oxidized low-density lipoprotein",
volume = "53",
number = "1",
pages = "29-34",
doi = "10.1515/cclm-2014-0590"
}
Obradović, M. M., Trpković, A., Bajić, V. P., Soskić, S. S., Jovanović, A., Stanimirović, J., Panic, M.,& Isenović, E. R.. (2015). Interrelatedness between C-reactive protein and oxidized low-density lipoprotein. in Clinical Chemistry and Laboratory Medicine, 53(1), 29-34.
https://doi.org/10.1515/cclm-2014-0590
Obradović MM, Trpković A, Bajić VP, Soskić SS, Jovanović A, Stanimirović J, Panic M, Isenović ER. Interrelatedness between C-reactive protein and oxidized low-density lipoprotein. in Clinical Chemistry and Laboratory Medicine. 2015;53(1):29-34.
doi:10.1515/cclm-2014-0590 .
Obradović, Milan M., Trpković, Andreja, Bajić, Vladan P., Soskić, Sanja S., Jovanović, Aleksandra, Stanimirović, Julijana, Panic, Milos, Isenović, Esma R., "Interrelatedness between C-reactive protein and oxidized low-density lipoprotein" in Clinical Chemistry and Laboratory Medicine, 53, no. 1 (2015):29-34,
https://doi.org/10.1515/cclm-2014-0590 . .
2
25
12
20